Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results today for the fiscal quarter ended December 31, 2014. The Corporation’s unaudited Q3...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders...
OTC Markets Group Welcomes Antibe Therapeutics to OTCQX® PR Newswire NEW YORK, Sept. 15, 2014 NEW YORK, Sept. 15, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.2156 | 0.2156 | 0.2156 | 0 | 0 | CS |
| 52 | -0.51325 | -70.4191534609 | 0.72885 | 0.8425 | 0.1113 | 25693 | 0.41012364 | CS |
| 156 | -0.3144 | -59.320754717 | 0.53 | 0.8855 | 0.1113 | 13431 | 0.47261356 | CS |
| 260 | -0.1344 | -38.4 | 0.35 | 5.88 | 0.1113 | 82128 | 0.64751355 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
